Suppr超能文献

WHIM 综合征由趋化因子受体 CXCR4 的羧基末端单个氨基酸取代引起。

WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4.

机构信息

Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

Blood. 2012 Jul 5;120(1):181-9. doi: 10.1182/blood-2011-12-395608. Epub 2012 May 17.

Abstract

WHIM syndrome is a rare, autosomal dominant, immunodeficiency disorder so-named because it is characterized by warts, hypogammaglobulinemia, infections, and myelokathexis (defective neutrophil egress from the BM). Gain-of-function mutations that truncate the C-terminus of the chemokine receptor CXCR4 by 10-19 amino acids cause WHIM syndrome. We have identified a family with autosomal dominant inheritance of WHIM syndrome that is caused by a missense mutation in CXCR4, E343K (1027G → A). This mutation is also located in the C-terminal domain, a region responsible for negative regulation of the receptor. Accordingly, like CXCR4(R334X), the most common truncation mutation in WHIM syndrome, CXCR4(E343K) mediated approximately 2-fold increased signaling in calcium flux and chemotaxis assays relative to wild-type CXCR4; however, CXCR4(E343K) had a reduced effect on blocking normal receptor down-regulation from the cell surface. Therefore, in addition to truncating mutations in the C-terminal domain of CXCR4, WHIM syndrome may be caused by a single charge-changing amino acid substitution in this domain, E343K, that results in increased receptor signaling.

摘要

WHIM 综合征是一种罕见的常染色体显性免疫缺陷病,因其具有疣、低丙种球蛋白血症、感染和骨髓嗜中性粒细胞减少(骨髓中中性粒细胞无法正常迁移)等特征而得名。导致 WHIM 综合征的是 CXCR4 趋化因子受体 C 端截断的功能获得性突变,该突变截断 10-19 个氨基酸。我们发现了一个 WHIM 综合征常染色体显性遗传家系,其致病原因为 CXCR4 的一个错义突变 E343K(1027G→A)。该突变也位于 C 端结构域,该区域负责受体的负调控。因此,与 WHIM 综合征最常见的截断突变 CXCR4(R334X)一样,CXCR4(E343K)在钙流和趋化性测定中引起的信号转导增加约 2 倍,而对正常受体从细胞表面的下调阻断作用则降低。因此,除了 CXCR4 C 端结构域的截断突变外,WHIM 综合征也可能由该结构域中的单个电荷变化氨基酸取代(E343K)引起,导致受体信号转导增强。

相似文献

8
CXCR4-Specific Nanobodies as Potential Therapeutics for WHIM syndrome.作为WHIM综合征潜在治疗药物的CXCR4特异性纳米抗体
J Pharmacol Exp Ther. 2017 Oct;363(1):35-44. doi: 10.1124/jpet.117.242735. Epub 2017 Aug 2.

引用本文的文献

6
The complex nature of CXCR4 mutations in WHIM syndrome.WHIM 综合征中 CXCR4 突变的复杂性。
Front Immunol. 2024 Jul 5;15:1406532. doi: 10.3389/fimmu.2024.1406532. eCollection 2024.
8
Mavorixafor: First Approval.莫维西福:首次获批。
Drugs. 2024 Aug;84(8):969-975. doi: 10.1007/s40265-024-02063-y. Epub 2024 Jul 15.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验